Skip to main content

Table 4 Comparison of data across studies

From: Efficacy and outcome of expanded newborn screening for metabolic diseases - Report of 10 years from South-West Germany *

  Wilcken et al., 2009[13]
Screened cohort born 1998-2002
N = 461,500
This study
Screened cohort born 1999-2009
N = 1,084,195
OR; 95% CI
Prevalence group 1: MSUD, BIOD, GA I, IVA, MCADD, CACTD, CPT
ID, CPT IID; LCHADD, VLCADD
n = 37
8.0:100,000
n = 122
11.25: 100,000
1.40; [0.97;2.02]
Prevalence group 2: Group 1 without MCADD n = 13
2.8: 100,000
n = 41
3.8: 100,000
1.34; [0.72;2.51]
MCADD    
Prevalence n = 24
5.2: 100,000
n = 81
7.5: 100,000
1.44; [0.91;2.27]
Clinical presentation by day 5 N = 2 N = 2  
Asymptomatic or clinical presentation after day 5 N = 22 N = 79  
Metabolic decompensation during follow-up Not reported 6/69  
Physical score nil significant at 6 (Australia)/3 (Heidelberg) years 22/22 31*/32  
No intellectual handicap at 6 (Australia)/3 (Heidelberg) years (IQ or intellectual development in normal range (IQ≥85)) 22/22 31*/32  
Normal school at ~6 yrs 15/15 9/9  
  1. Abbreviations see Table 1
  2. * one patient never showing a metabolic decompensation but congenital cardiomyopathy of unknown origin. The clinical signs of two of three MCADD patients with a "positive" clinical status score (Table 3) were judged as non significant (see text).